A Single-Center Study To Evaluate The Safety and Efficacy of Sofosbuvir Plus Ribavirin In Patients With Severe Hepatitis C Recurrence After Liver Transplantation.
Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 01 May 2017
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Acronyms ITACOPS
- Sponsors Gilead Sciences
- 16 Sep 2015 Interim results (n = 116) presented at the 17th Congress of the European Society for Organ Transplantation.
- 12 Aug 2015 New trial record